Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Phase 1 Terminated 5 enrolled Longeveron Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is intended to evaluate the safety and feasibility of intramyocardial injection of allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA) surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.

Timeline

Start: 2015-04
Primary completion: 2019-03
Completion: 2019-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rexlemestrocel-L	Cell therapy	250000 cells/kg	Other

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Summary

Timeline

Drugs

Indications